Zealand Pharma, a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, announces the acquisition of Encycle Therapeutics, a private Toronto-based biotech company exploiting a unique platform technology that enables the rapid synthesis of macrocyclic peptides exhibiting enhanced drug-like properties.
Verseau Therapeutics, Inc. (“Verseau”) launched with $50 million in financing from 20/20 HealthCare Partners, 3SBio, Alexandria Venture Investments, Highlight Capital, InHarv Partners Ltd., The Mark Foundation for Cancer Research and Yonghua Capital.
Alexion Pharmaceuticals has agreed to acquire clinical-stage biopharmaceutical company Achillion Pharmaceuticals in a deal valued at around $930m.
CRISPR Therapeutics and KSQ Therapeutics have signed license agreement to advance their respective cell therapy programmes in oncology.
Belgium-based biopharmaceutical firm UCB has agreed to acquire US-based clinical-stage biopharmaceutical company Ra Pharmaceuticals in a deal valued at around $2.1bn.
Alexion Pharmaceuticals and Stealth BioTherapeutics have announced an agreement for an option to co-develop and commercialize elamipretide for mitochondrial diseases.
Viela Bio has entered into a licensing deal with Mitsubishi Tanabe Pharma to develop and commercialize inebilizumab in nine Asian countries for the treatment of autoimmune and inflammatory diseases.
Global public health organisation NSF International has purchased a majority stake in US-based clinical stage contract research organisation (CRO) called Amarex Clinical Research.
Akcea Therapeutics, a majority-owned affiliate of Ionis Pharmaceuticals, has signed an agreement to license investigative antisense therapy AKCEA-ANGPTL3-LRx to pharmaceutical company Pfizer.
Johnson & Johnson has unveiled plans to invest over $500m in the next four years to help end the epidemics of HIV and tuberculosis (TB).
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.